NVO: Impulsive Sequence Favors Upside & Remain Supported

Novo Nordisk A/S (NVO), a healthcare company engages in the research, development, manufacture and marketing of the pharmaceutical products worldwide.

Novo Nordisk A/S (NVO), a healthcare company engages in the research, development, manufacture and marketing of the pharmaceutical products worldwide. It operates in two segments, Diabetes & Obesity care & Biopharm. It is based in Denmark, comes under Healthcare - Biotechnology sector & trades as “NVO” ticker at NYSE.

NVO is showing higher high clear impulse sequence in over the years. So, it expects to remain supported in 3, 7 or 11 swings at extreme areas in pullback. Currently, it favors correction in ((2)) of V of (I) before turning higher in ((3)) of V.

NVO - Monthly Elliott Wave Latest View: 

It placed wave ((I)) at $60.34 as Grand super cycle in 2015 & ((II)) at $30.89 low in 2016. Above there, it favors higher in (I) of ((III)). It favored ended I of (I) at $58.37 high & (II) at $41.23 low as 0.618 Fibonacci retracement. Above there, it extended higher in third wave extension, ended at $122.16 high. Wave IV finished at $95.02 low as slightly above 0.382 Fibonacci retracement. Currently, it favors higher in V as it already confirms higher high sequence.

NVO - Weekly Elliott Wave Latest View: 

In wave V, it placed (1) of ((1)) at $106.43 high & (2) at $100.89 low. Above there, it favored ended (3) at $139.05 high as third wave extended wave & (4) at $130.10 low. Finally, it ended (5) as ((1)) at $144.78 high & correcting in ((2)) in 7 or 11 swings towards $130.04 - $121.70 area before upside resumes in (1) of ((3)) of V. Alternatively, it may ended ((2)) at $131.17 low & favors higher in (1) of ((3)) of V or else, it may do double in ((2)) correction before turning higher in ((3)).

Source: https://elliottwave-forecast.com/stock-market/nvo-impulsive-sequence-favors-upside-remain-supported/

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

STOCKS IN THIS BLOG POST

Comments